By Counterforce Health Team in Gamifant (emapalumab-lzsg) —

How to Get Gamifant (Emapalumab-lzsg) Covered by UnitedHealthcare in Illinois: Prior Authorization Guide 2025

Answer Box: Getting Gamifant Approved by UnitedHealthcare in Illinois

UnitedHealthcare requires prior authorization for Gamifant (emapalumab-lzsg) as a medical-benefit specialty drug for primary HLH. Key requirements: confirmed HLH-2004 diagnostic criteria (≥5 of 8 criteria or genetic confirmation), documented failure of conventional therapy (dexamethasone + etoposide), and FDA-label dosing plan. Submit via the UHC Provider Portal with complete clinical documentation. Standard review takes 5-15 business days; expedited review available for urgent cases within 24-72 hours. If denied, Illinois residents have strong appeal rights including external review through the Illinois Department of Insurance within 4 months of final denial.

Table of Contents

  1. Before You Start: Plan Verification
  2. Coverage Requirements at a Glance
  3. Step-by-Step: Fastest Path to Approval
  4. Required Clinical Documentation
  5. Common Denial Reasons & How to Fix Them
  6. Appeals Process in Illinois
  7. Cost Assistance and Support
  8. FAQ
  9. Sources & Further Reading

Before You Start: Plan Verification

Check Your UnitedHealthcare Plan Type

First, confirm whether your UnitedHealthcare plan is subject to Illinois state regulations or federal ERISA rules:

  • Fully insured plans (individual, small group): Subject to Illinois external review laws
  • Self-funded employer plans: Follow federal appeal processes
  • Medicare Advantage: Federal timelines with some Illinois overlay
  • Medicaid managed care: Illinois Medicaid appeal rights apply
Tip: Your insurance card or HR department can confirm your plan type. This determines which appeal process you'll use if denied.

Verify Gamifant is a Medical Benefit Drug

UnitedHealthcare treats Gamifant as a medical-benefit specialty drug, not a pharmacy benefit. This means:

  • Prior authorization routes through UHC's medical drug PA process
  • Billing occurs under your medical benefit (not pharmacy)
  • Dispensing happens via contracted specialty pharmacy or infusion center
  • Administration typically occurs in hospital outpatient or infusion center setting

Coverage Requirements at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required for all UHC plans UHC PA Requirements List
Diagnosis Primary HLH meeting HLH-2004 criteria HLH-2004 Protocol
Step Therapy Failed conventional therapy (dex + etoposide) UHC Gamifant Policy
FDA-Label Use Refractory/recurrent/progressive primary HLH FDA Label
Specialty Pharmacy Must use contracted specialty pharmacy Verify via UHC Provider Portal
Authorization Duration Initial approval ≤6 months UHC Medical Drug Policy

Step-by-Step: Fastest Path to Approval

Step 1: Confirm HLH-2004 Diagnostic Criteria

Who: Treating hematologist
Timeline: Before PA submission

Document that the patient meets ≥5 of 8 HLH-2004 criteria OR has genetic confirmation of primary HLH:

  1. Fever >38.5°C
  2. Splenomegaly
  3. Cytopenias (≥2 lineages): Hgb <9 g/dL, platelets <100×10⁹/L, neutrophils <1.0×10⁹/L
  4. Hypertriglyceridemia (≥265 mg/dL) and/or hypofibrinogenemia (≤1.5 g/L)
  5. Hemophagocytosis in bone marrow/spleen/lymph nodes
  6. Low/absent NK-cell activity
  7. Hyperferritinemia (≥500 μg/L)
  8. Elevated soluble CD25 (≥2400 U/mL)

Step 2: Document Conventional Therapy Failure

Who: Treating physician
Timeline: Include in PA submission

Provide specific evidence of failure, intolerance, or contraindication to:

  • Dexamethasone (doses, dates, response)
  • Etoposide (doses, dates, objective failure metrics)
  • Cyclosporine (if used in protocol)

Include objective measures like ferritin trends, persistent fever, worsening cytopenias, or organ dysfunction.

Step 3: Submit Prior Authorization

Who: Provider or clinic staff
Timeline: Allow 5-15 business days for standard review

Submit via UHC Provider Portal with:

  • Completed medical drug PA form
  • HLH-2004 criteria documentation with lab values and dates
  • Treatment history with objective outcomes
  • Proposed Gamifant dosing plan per FDA label
  • Infection screening results

For urgent cases, call 1-800-711-4555 to request expedited review (24-72 hours).

Step 4: Coordinate Specialty Pharmacy

Who: Clinic coordinator
Timeline: After PA approval

Once approved, coordinate with UHC's designated specialty pharmacy (often Biologics, Inc.) for:

  • Drug ordering and shipment
  • Delivery to infusion site
  • Administration scheduling

Required Clinical Documentation

Medical Necessity Letter Checklist

Your letter should include:

Diagnosis Section:

  • ICD-10 code (typically D76.1 for primary HLH)
  • Clear statement: "Patient meets ≥5 of 8 HLH-2004 diagnostic criteria"
  • Table listing which criteria are met with specific lab values and dates
  • Genetic testing results if available

Treatment History Section:

  • Complete conventional therapy history with:
    • Drug names, doses, start/stop dates
    • Objective response measures (ferritin, fever resolution, cytopenia improvement)
    • Specific reasons for failure (progressive disease, intolerance, contraindications)

Clinical Rationale Section:

  • Current disease status and severity
  • Why continued conventional therapy is inadequate
  • Treatment goals with Gamifant
  • Planned monitoring and response assessment

FDA-Label Alignment:

  • Proposed dosing consistent with FDA labeling
  • Administration plan and site of care
  • Infection screening completed per label requirements
From our advocates: In our experience helping families navigate HLH coverage, the strongest PA submissions include a clear timeline showing disease progression despite conventional therapy, with specific lab trends rather than general statements like "failed to respond." This objective evidence makes the medical necessity case much clearer to reviewers.

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn
HLH diagnosis not confirmed Submit detailed HLH-2004 criteria table with lab values, dates, and genetic testing if available
Insufficient conventional therapy trial Provide complete treatment history with doses, duration, and objective failure metrics (ferritin trends, persistent symptoms)
Missing infection workup Include TB screening, viral studies, and other infection screening per FDA label
Off-label use concern Confirm primary HLH indication and cite FDA approval for refractory/recurrent/progressive disease
Site of care issues Verify infusion center is in-network and meets UHC site-of-care requirements

Appeals Process in Illinois

Internal Appeal (First Level)

Timeline: File within 60 days of denial
Decision: Within 30 days (72 hours if expedited)

  1. Submit written appeal via UHC Provider Portal or mail
  2. Include denial letter and additional clinical documentation
  3. Request peer-to-peer review between treating hematologist and UHC medical director
  4. Address each specific denial reason with evidence

External Review (Illinois-Specific)

Timeline: File within 4 months of final internal denial
Decision: Within 21-45 days

For fully insured Illinois plans:

  1. Complete Illinois External Review Form
  2. Submit to Illinois Department of Insurance
  3. Independent Review Organization (IRO) conducts binding review
  4. IRO decision compels UHC to cover if overturned

Illinois DOI Consumer Assistance: 877-527-9431

Note: Illinois has a shorter external review filing deadline (4 months) compared to some states, so act promptly after final internal denial.

Cost Assistance and Support

Manufacturer Support Programs

  • Gamifant Cares: Patient support program offering financial assistance
  • Website: gamifantcares.com
  • Eligibility: Based on insurance coverage and financial need

Illinois-Specific Resources

  • Illinois Attorney General Health Care Bureau: 1-877-305-5145
  • Citizen Action/Illinois: Consumer advocacy for complex insurance cases
  • Legal aid organizations: May assist with appeal documentation for rare disease cases

FAQ

How long does UnitedHealthcare prior authorization take in Illinois? Standard review takes 5-15 business days. Expedited review for urgent cases is completed within 24-72 hours. UHC PA timelines apply nationally.

What if Gamifant is non-formulary on my plan? Gamifant is typically covered as a medical-benefit drug rather than appearing on pharmacy formularies. Check your plan's medical drug coverage rather than prescription drug formulary.

Can I request expedited appeal in Illinois? Yes, if delay would seriously jeopardize life or health. Your physician must certify urgency. Expedited appeals receive decisions within 48-72 hours.

Does step therapy apply if I failed conventional therapy outside Illinois? Yes, UHC accepts documented treatment failure from any qualified provider, regardless of location, as long as the documentation meets their clinical criteria.

What happens if my external review is denied? External review decisions are binding. However, you may be able to resubmit if new clinical evidence becomes available or if there were procedural issues with the initial review.

How often do I need to renew Gamifant authorization? Initial approvals are typically limited to 6 months. Renewals require documentation of clinical benefit (improved labs, reduced transfusion needs, fever resolution).

Sources & Further Reading

Counterforce Health helps patients, clinicians, and specialty pharmacies get prescription drugs approved by turning insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters and plan policies to draft point-by-point rebuttals aligned to payer requirements, pulling the right citations for medications and weaving them into appeals with required clinical facts. For complex cases like Gamifant approvals, having systematic appeal support can make the difference between coverage and continued denials. Learn more at www.counterforcehealth.org.

This guide is for informational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for specific coverage decisions. For personalized assistance with Illinois insurance appeals, contact the Illinois Department of Insurance Consumer Services at 877-527-9431.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.